---
figid: PMC9482625__41392_2022_1168_Fig3_HTML
figtitle: Cellular composition within the TME and the effect of EMT on TKI resistance
organisms:
- Candida dubliniensis
- Lareunionomyces loeiensis
- Piper longum
- Homo sapiens
- Mus musculus
- Danio rerio
- NA
organisms_ner:
- Homo sapiens
- Mus musculus
- Danio rerio
- Drosophila melanogaster
pmcid: PMC9482625
filename: 41392_2022_1168_Fig3_HTML.jpg
figlink: /pmc/articles/PMC9482625/figure/Fig3/
number: F3
caption: Cells within the TME include tumor cells, cancer-associated stromal cells,
  and immune cells. These cells crosstalk with other cells through cytokines and chemokines,
  promoting tumor progression. Some cell-secreted ligands, such as TGF-β, IL-6, HGF,
  IGF, etc., can bind to the corresponding receptors on the surface of tumor cells
  and affect the biological behavior of tumor cells, one of which is EMT. EMT can
  be mediated by the TGFβ/Smad classical pathway. Some cytokine receptors, such as
  IL-6 and some RTKs (AXL, FGFR, MET, IGFR, TrkA, etc.) can also activate the PI3K/AKT,
  RAS/MAPK, and JAK/STAT pathways in combination with the corresponding ligands to
  induce EMT. The Notch signaling pathway and wnt/β-catenin pathway are also involved
  in EMT, and there is crosstalk between these pathways. Tumor cells that develop
  EMT have a more aggressive phenotype and metastatic ability and are resistant to
  cell death and TKI resistance. In addition, the immunosuppressive state within the
  TME impairs the killing of tumor cells by immune cells and promotes tumor survival
papertitle: 'Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular
  mechanisms and future perspective.'
reftext: Yang Yang, et al. Signal Transduct Target Ther. 2022;7:329.
year: '2022'
doi: 10.1038/s41392-022-01168-8
journal_title: Signal Transduction and Targeted Therapy
journal_nlm_ta: Signal Transduct Target Ther
publisher_name: Nature Publishing Group UK
keywords: Cancer
automl_pathway: 0.9237757
figid_alias: PMC9482625__F3
figtype: Figure
redirect_from: /figures/PMC9482625__F3
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC9482625__41392_2022_1168_Fig3_HTML.html
  '@type': Dataset
  description: Cells within the TME include tumor cells, cancer-associated stromal
    cells, and immune cells. These cells crosstalk with other cells through cytokines
    and chemokines, promoting tumor progression. Some cell-secreted ligands, such
    as TGF-β, IL-6, HGF, IGF, etc., can bind to the corresponding receptors on the
    surface of tumor cells and affect the biological behavior of tumor cells, one
    of which is EMT. EMT can be mediated by the TGFβ/Smad classical pathway. Some
    cytokine receptors, such as IL-6 and some RTKs (AXL, FGFR, MET, IGFR, TrkA, etc.)
    can also activate the PI3K/AKT, RAS/MAPK, and JAK/STAT pathways in combination
    with the corresponding ligands to induce EMT. The Notch signaling pathway and
    wnt/β-catenin pathway are also involved in EMT, and there is crosstalk between
    these pathways. Tumor cells that develop EMT have a more aggressive phenotype
    and metastatic ability and are resistant to cell death and TKI resistance. In
    addition, the immunosuppressive state within the TME impairs the killing of tumor
    cells by immune cells and promotes tumor survival
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - FZD1
  - FZD10
  - FZD2
  - FZD3
  - FZD4
  - FZD5
  - FZD6
  - FZD7
  - FZD8
  - FZD9
  - SOAT1
  - STAT1
  - STAT2
  - STAT3
  - STAT4
  - STAT6
  - STAT5A
  - STAT5B
  - JAK1
  - JAK2
  - JAK3
  - TYK2
  - CTNNB1
  - NOTCH1
  - NOTCH2
  - NOTCH3
  - NOTCH4
  - TWIST1
  - ZEB2
  - ZEB1
  - VEGFA
  - VEGFB
  - VEGFC
  - VEGFD
  - PGF
  - PDGFA
  - PDGFB
  - PDGFC
  - PDGFD
  - CSF2
  - CSF3
  - TBX1
  - SMAD4
  - TGFB1
  - TGFB2
  - TGFB3
  - SMAD2
  - SMAD3
  - SNAI1
  - MIR34A
  - CXCL8
  - IL6
  - IGF1
  - HGF
  - SOS1
  - AXL
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - AKT1
  - AKT2
  - AKT3
  - FGFR1
  - FGFR2
  - FGFR3
  - FGFR4
  - FGFRL1
  - MAPK1
  - MAPK3
  - MAPK11
  - MAPK12
  - MAPK13
  - MAPK14
  - MAPK8
  - MAPK9
  - MAPK10
  - EPHB2
  - TGFA
  - ITK
  - SLC22A3
  - CCL2
  - HIF1A
  - EPAS1
  - HIF3A
  - ARNT
  - ARNT2
  - BMAL1
  - EREG
  - CCL15
  - CCL15-CCL14
  - CD8A
  - CD8B
  - CDH1
  - FZR1
  - Ctnnb1
  - Twist1
  - Zeb2
  - Zeb1
  - Vegfa
  - Csf2
  - Csf3
  - Pbrgcsf1
  - Smad4
  - Tgfb1
  - Ltbp1
  - Smad2
  - Smad3
  - Snai1
  - Mir34a
  - Cxcl15
  - Il6
  - Hgf
  - Met
  - Axl
  - Pik3r1
  - Akt1
  - Ephb2
  - Mapk1
  - Tgfa
  - Itk
  - Slc22a3
  - Ccl2
  - Ereg
  - Cdh1
  - Fzr1
  - Dab1
  - stat1b
  - stat4
  - ctnnb1
  - twist1a
  - zeb1b
  - vegfaa
  - csf3b
  - csf3a
  - smad4a
  - smad4b
  - kita
  - ngfra
  - smad2
  - smad3a
  - mir34a
  - cxcl8a
  - il6
  - igfn1.2
  - axl
  - foxa2
  - tgfa
  - ccl38a.5
  - cdh1
  - si:busm1-180o5.1
  - si:busm1-180o5.2
  - gli2a
  - fz
  - Stat92E
  - hop
  - bsk
  - arm
  - .na.character
  - Pvf1
  - Pvf2
  - Pvf3
  - Pvr
  - Med
  - dpp
  - gbb
  - put
  - mav
  - Smox
  - sna
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - Akt
  - btl
  - htl
  - MKP-4
  - p38b
  - rl
  - Erk7
  - tant
  - shg
  - RpL23
---
